Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gritstone bio, Inc.GRTS · Entity 80946 | EVP and General Counsel | January 31, 2022 | April 20, 2022 |
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Chief Legal Officer | February 24, 2023 | February 28, 2023 |
| OPIANT PHARMACEUTICALS, INC.OPNT · Entity 115992 | General Counsel | September 20, 2019 | September 20, 2019 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Chief Legal & Compliance | August 14, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gritstone bio, Inc.
Report date January 31, 2022 · Filed April 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,698 |
Reported balance
After 2022-01-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-31 · Grant · Acquired 19,240 · Balance 58,698 F1: Represents Restricted Stock Units ("RSUs") which vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2: Includes 13,958 shares of common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c) and 31,990 RSUs which vest over time measured from the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2032-01-30 | Direct | 115,440 |
Reported balance
After 2022-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-31 · Grant · Acquired 115,440 · Balance 115,440 F3: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from January 31, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") which vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: Includes 13,958 shares of common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c) and 31,990 RSUs which vest over time measured from the grant date.
F3: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from January 31, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Lyell Immunopharma, Inc.
Report date February 24, 2023 · Filed February 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.13 · Expires 2033-02-23 | Direct | 245,000 |
Reported balance
After 2023-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-24 · Grant · Acquired 245,000 · Balance 245,000 F1: 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months. |
Filing footnotes · ownership attribution and instrument terms
F1: 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.
OPIANT PHARMACEUTICALS, INC.
Report date September 20, 2019 · Filed September 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,500 |
Reported balance
Holding disclosure · report date 2019-09-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,500 F1: 13,500 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of September 15, 2020, September 15, 2021, September 15, 2022 and September 15, 2023, subject to the Reporting Person continuing as a service provider through each such date. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.51 · Expires 2030-09-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-20 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: One-fourth of the shares subject to the option vest on September 16, 2020 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 13,500 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of September 15, 2020, September 15, 2021, September 15, 2022 and September 15, 2023, subject to the Reporting Person continuing as a service provider through each such date.
F2: One-fourth of the shares subject to the option vest on September 16, 2020 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
ZEVRA THERAPEUTICS, INC.
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,569 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Sale · Disposed 42,666 · Balance 37,569 F1: Adoption date of referenced 10b5-1(c) plan is: 05-15-2026 F2: This transaction was executed in multiple trades at prices ranging from $10.86 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Adoption date of referenced 10b5-1(c) plan is: 05-15-2026
F2: This transaction was executed in multiple trades at prices ranging from $10.86 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 20:32 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 42,666 | $11.13 | $474,774.45 |
DisclosureSEC source: 0001434647-26-000073 · wk-form4_1786998758.xml · nonDerivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,569 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 05-15-2026 F2 · price: This transaction was executed in multiple trades at prices ranging from $10.86 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 34,557 | $12.68 | $438,303.71 |
DisclosureSEC source: 0001434647-26-000057 · wk-form4_1782245786.xml · nonDerivative · entry 2 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,235 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 01-08-2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $12.53 to $13.19. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2026 Filed Jun 23, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 66,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001434647-26-000057 · wk-form4_1782245786.xml · derivative · entry 3 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 66,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The first and second tranches of the restricted stock units vested and settled on June 21, 2025 and June 21, 2026, respectively, and the remaining tranche of the restricted stock units will vest and settle on the next anniversary thereafter, subject to the Reporting person's continued service through such vesting date. F4 · derivative.expiration_date: The first and second tranches of the restricted stock units vested and settled on June 21, 2025 and June 21, 2026, respectively, and the remaining tranche of the restricted stock units will vest and settle on the next anniversary thereafter, subject to the Reporting person's continued service through such vesting date. Read SEC document |
| June 21, 2026 Filed Jun 23, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 66,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001434647-26-000057 · wk-form4_1782245786.xml · nonDerivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:32 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 1,794 | $11.30 | $20,272.20 |
DisclosureSEC source: 0001434647-26-000034 · wk-form4_1778704324.xml · nonDerivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,125 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 01-08-2026 Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001788524-26-000002 · wk-form4_1770070782.xml · derivative · entry 5 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 11,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date. F6 · derivative.expiration_date: One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 4,080 | $8.83 | $36,009.67 |
DisclosureSEC source: 0001788524-26-000002 · wk-form4_1770070782.xml · nonDerivative · entry 2 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,919 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 3/27/2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $8.58 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 11,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001788524-26-000002 · wk-form4_1770070782.xml · nonDerivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001788524-26-000002 · wk-form4_1770070782.xml · derivative · entry 4 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-01-28 F5 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001788524-26-000002 · wk-form4_1770070782.xml · derivative · entry 3 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. F4 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 21:02 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 24,000 | $9.21 | $221,004.00 |
DisclosureSEC source: 0001437749-25-021577 · rdgdoc.xml · nonDerivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,666 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 03-27-2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.11 to $9.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 21, 2025 Filed Jun 24, 2025 21:28 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 66,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-021183 · rdgdoc.xml · derivative · entry 2 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,334 Underlying: Common Stock · 66,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The first tranche of the restricted stock units vested and settled on June 21, 2025, and the remaining two tranches of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. F2 · derivative.expiration_date: The first tranche of the restricted stock units vested and settled on June 21, 2025, and the remaining two tranches of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| June 21, 2025 Filed Jun 24, 2025 21:28 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 66,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-021183 · rdgdoc.xml · nonDerivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 22:23 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002628 · rdgdoc.xml · derivative · entry 2 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 30, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. F3 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 30, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 22:23 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001437749-25-002628 · rdgdoc.xml · derivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2035-01-29 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:13 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-021191 · rdgdoc.xml · derivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal & Compliance · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units ("RSU") under the Issuer's 2023 Employment Inducement Award Plan (the "Plan"). 33 1/3% of the shares will vest on June 21, 2025 and the remainder vesting in two equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. F1 · derivative.expiration_date: Grant to the Reporting Person of restricted stock units ("RSU") under the Issuer's 2023 Employment Inducement Award Plan (the "Plan"). 33 1/3% of the shares will vest on June 21, 2025 and the remainder vesting in two equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:15 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 245,000 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001209191-23-013839 · doc4.xml · derivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 245,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 20:10 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 715,000 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001209191-22-053457 · doc4.xml · derivative · entry 1 Thompson Rahsaan · CIK 0001788524 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715,000 Underlying: Common Stock · 715,000 shares Expires 2032-10-09 F1 · derivative.exercise_date: 1/4 of the option shares shall vest on September 28, 2023, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. Read SEC document |
| January 31, 2022 Filed Apr 20, 2022 16:43 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 115,440 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001567619-22-008723 · doc1.xml · derivative · entry 2 Thompson Rahsaan · CIK 0001788524 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,440 Underlying: Common Stock · 115,440 shares Expires 2032-01-30 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from January 31, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| January 31, 2022 Filed Apr 20, 2022 16:43 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantCommon Stock | 19,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008723 · doc1.xml · nonDerivative · entry 1 Thompson Rahsaan · CIK 0001788524 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,698 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes 13,958 shares of common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c) and 31,990 RSUs which vest over time measured from the grant date. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 17:10 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $13.87 | $0.00 |
DisclosureSEC source: 0001567619-21-005998 · doc1.xml · derivative · entry 1 Thompson Rahsaan · CIK 0001788524 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-07 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 8, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| January 07, 2021 Filed Nov 19, 2021 17:37 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantCommon Stock | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-020875 · doc1.xml · nonDerivative · entry 1 Thompson Rahsaan · CIK 0001788524 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,487 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in two equal annual installments over a two year period measured from the grant date. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes 3,987 shares of common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c) and 25,500 RSUs which vest over time measured from the grant date. Read SEC document |
| May 13, 2020 Filed May 15, 2020 17:07 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001567619-20-010601 · doc1.xml · derivative · entry 1 Thompson Rahsaan · CIK 0001788524 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the total number of shares on April 6, 2021. The remaining shares vest and become exercisable in equal monthly installments over the following 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.